依曲帕米鼻喷雾剂快速转复室上性心动过速为窦性心律
主要终点为给药后15分钟内SVT转复率,依曲帕米组转复率介于65%至95%,安慰剂组为35%,最高3个活性剂量组与安慰剂差异有统计学意义;转复者中位转复时间<3分钟,不良事件多与鼻内给药途径或局部刺激相关,血压下降主要见于最高剂量组。
要点
- 依曲帕米鼻喷雾剂可在15分钟内快速转复诱发的SVT,转复率65%–95%。
- 转复者中位转复时间<3分钟,不良事件以鼻内给药相关局部刺激为主。
- 血压下降主要见于最高剂量组,为后续剂量选择提供参考。
核心结论
- 依曲帕米鼻喷雾剂可快速终止诱发的SVT,转复率高,安全性结果可为后续真实世界自我给药研究的剂量选择提供指导。
研究设计与样本
- 2期研究,在既往有SVT记录且电生理检查中诱发SVT并拟行导管消融的患者中进行。
主要发现
- 依曲帕米鼻喷雾剂组SVT转复为窦性心律的转复率介于65%至95%,安慰剂组为35%。
- 最高3个活性剂量组与安慰剂比较差异有统计学意义(Pearson卡方检验)。
- 转复患者中,依曲帕米的中位转复时间<3分钟。
- 不良事件大多与鼻内给药途径或局部刺激相关。
- 血压下降主要发生在最高依曲帕米剂量组。
临床怎么用
- 依曲帕米鼻喷雾剂有望作为SVT快速转复的非肠道外给药选择,但需关注局部刺激和最高剂量相关血压下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no nonparenteral medication for the rapid termination of paroxysmal supraventricular tachycardia. OBJECTIVES: The purpose of this study was to assess the efficacy and safety of etripamil nasal spray, a short-acting calcium-channel blocker, for the rapid termination of paroxysmal supraventricular tachycardia (SVT). METHODS: This phase 2 study was performed during electrophysiological testing in patients with previously documented SVT who were induced into SVT prior to undergoing a catheter ablation. Patients in sustained SVT for 5 min received either placebo or 1 of 4 doses of active compound. The primary endpoint was the SVT conversion rate within 15 min of study drug administration. Secondary endpoints included time to conversion and adverse events. RESULTS: One hundred four patients were dosed. Conversion rates from SVT to sinus rhythm were between 65% and 95% in the etripamil nasal spray groups and 35% in the placebo group; the differences were statistically significant (Pearson chi-square test) in the 3 highest active compound dose groups versus placebo. In patients who converted, the median time to conversion with etripamil was <3 min. Adverse events were mostly related to the intranasal route of administration or local irritation. Reductions in blood pressure occurred predominantly in the highest etripamil dose. CONCLUSIONS: Etripamil nasal spray rapidly terminated induced SVT with a high conversion rate. The safety and efficacy results of this study provide guidance for etripamil dose selection for future studies involving self-administration of this new intranasal calcium-channel blocker in a real-world setting for the termination of SVT. (Efficacy and Safety of Intranasal MSP-2017 [Etripamil] for the Conversion of PSVT to Sinus Rhythm [NODE-1]; NCT02296190).
引用
- Stambler BS, Dorian P, Sager PT, et al. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018. PMID: 30049309. doi:10.1016/j.jacc.2018.04.082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。